FDA-Approved MedicationUpdated November 2026

Foundayo Guide

Foundayo (orforglipron) is the first FDA-approved once-daily oral small-molecule GLP-1 receptor agonist for chronic weight management. Approved by the FDA on April 1, 2026, Foundayo is taken as a single tablet once a day with no food or water restrictions, marking a major change from injectable GLP-1s and from oral semaglutide (Rybelsus), which has strict food and water rules. In the 72-week ATTAIN-1 phase 3 trial, the label reports 11.1% mean weight loss on the 17.2 mg dose versus 2.1% on placebo (12.4% versus 0.9% under the trial's efficacy estimand).

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed

At a Glance

Generic NameOrforglipron
Brand NamesFoundayo
FDA StatusFDA-approved for chronic weight management in adults with obesity, or overweight with weight-related medical problems, alongside a reduced-calorie diet and increased physical activity (April 1, 2026). Not approved for pediatric use. Use with another GLP-1 receptor agonist is not recommended.[1]
Approval DateApril 1, 2026[1]

How Foundayo Works

Orforglipron is a non-peptide small molecule that binds and activates the GLP-1 receptor directly. Unlike injectable GLP-1 peptides (semaglutide, tirzepatide) or oral peptide formulations (Rybelsus), orforglipron is a true small organic molecule that survives stomach acid and digestion, eliminating the need for injection or special food restrictions. It produces the same downstream effects as injectable GLP-1 agonists: appetite suppression, slowed gastric emptying, and reduced food reward signaling.[2]

Dosing Schedule

Foundayo uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].

Starting dose0.8 mg orally once daily
TitrationStepwise increase: 2.5 mg, 5.5 mg, 9 mg
Higher doses14.5 mg, then 17.2 mg (label maximum; 9 mg maximum with a strong CYP3A4 inhibitor)

Side Effects

Common: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, swollen belly, fatigue, belching, heartburn, gas, hair loss. Serious: pancreatitis, dehydration leading to kidney problems, gallbladder disease, hypoglycemia (especially with insulin/sulfonylureas), serious allergic reactions, diabetic retinopathy progression in T2D patients, increased aspiration risk during anesthesia. Boxed warning: risk of thyroid C-cell tumors, carried as a GLP-1 class warning; orforglipron itself is not pharmacologically active in rats or mice and did not produce tumors in rodents. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).[1][2]

This is not a complete list. Consult your healthcare provider or prescriber for full safety information. The complete adverse reaction profile is published in the current FDA prescribing information[1].

Clinical Trial Results

ATTAIN-1 (NCT05869903) was a 72-week phase 3 randomized placebo-controlled trial of 3,127 adults with obesity or overweight plus a weight-related comorbidity (no diabetes), conducted across 10 countries. Highest dose produced 12.4% mean body weight reduction (~27 lbs) versus 0.9% on placebo (efficacy estimand). Treatment-regimen estimand: 11.1% (~25 lbs) vs 2.1% placebo. Foundayo also reduced waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure across all doses. ATTAIN-2, in patients with type 2 diabetes, has since been published.[2]

Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

Where to Get Foundayo

These telehealth providers offer access to orforglipron with online consultations and home delivery. Before you book a consult, our guide to getting Foundayo online walks through eligibility, the prescriber visit, and what legitimate pharmacy fulfillment looks like.

8.3/ 10
Partner

Found

Best for: medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help

★★★★☆4.2/5

Editorial score · methodology

$289/4 wkssemaglutide
billed per 4 weeks
$359/4 wkstirzepatide
billed per 4 weeks
CompoundedSemaglutideTirzepatideOrforglipron
Get StartedRead full Found review →
8.0/ 10
Partner

Sesame Care

Best for: Brand-name GLP-1s at cash prices, no compounding

★★★★☆4/5

Editorial score · methodology

$149/mosemaglutide
see plan details
BrandSemaglutideTirzepatideOrforglipron
Get StartedRead full Sesame Care review →
8.0/ 10
Partner

ShedRx

Best for: compounded GLP-1 as an injection, drops or lozenges, with lower rates on 6- and 12-month plans

★★★★☆4/5

Editorial score · methodology

$199/mosemaglutide
plan-length pricing
$279/motirzepatide
“starting at” price
CompoundedSemaglutideTirzepatideOrforglipronGHK-Cu
Get StartedRead full ShedRx review →
7.7/ 10
Partner

Ro

Best for: FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help

★★★★☆3.9/5

Editorial score · methodology

$149/mosemaglutide
+ required membership
BrandSemaglutideTirzepatideOrforglipron
Get StartedRead full Ro review →
7.6/ 10
Partner

Maximus

Best for: men seeking compounded tirzepatide alongside testosterone optimization

★★★★☆3.8/5

Editorial score · methodology

$100/mosemaglutide
microdose plan
$100/motirzepatide
12-month plan rate
CompoundedSemaglutideTirzepatideOrforglipronSermorelinFDA Warning
Get StartedRead full Maximus review →
7.6/ 10
Partner

SkinnyRx

Best for: compounded semaglutide or tirzepatide with the consult and free overnight shipping in one price

★★★★☆3.8/5

Editorial score · methodology

$99/mosemaglutide
intro price
$299/motirzepatide
after intro offer
CompoundedSemaglutideTirzepatideOrforglipronSermorelinFDA Warning
Get StartedRead full SkinnyRx review →

Each provider's lowest ongoing monthly cash price for Foundayo, sorted cheapest first (no copays, membership fees or intro offers). Both compounded and brand-name prescriptions are generally FSA/HSA eligible under IRS Publication 502[5]. Prices may vary based on dose.

ProviderFrom (ongoing)
Amazon One Medical$149/momedication billed separatelyVisit
Found$149/mo+ required membershipVisit
GoodRx$149/morises with doseVisit
Healthspan$149/mo+ required membershipVisit
Hers$149/mo+ required membershipVisit
Hims$149/mo+ required membershipVisit
HuHealth$149/mosee plan detailsVisit
Imbue Health$149/mo+ required membershipVisit
LillyDirect Foundayo$149/moVisit
Médetone$149/mo+ required membershipVisit
PrideRx$149/mo+ required membershipVisit
Ro$149/mo+ required membershipVisit
Sesame Care$149/mosee plan detailsVisit
ShedRx$149/mo+ required membershipVisit
Temi$149/morises with doseVisit
Walgreens Weight Management$149/momedication billed separatelyVisit
ZipHealth$149/mosee plan detailsVisit
PreventiveMD$198/mo“starting at” priceVisit
Maximus$200/mostarting doseVisit
Alloy$248/mostarting doseVisit
Phoenix NP$248/moper 4 weeksVisit
SkinnyRx$248/mo“starting at” priceVisit
Näky$424/mo+ added feeVisit
Pallas Health$499/moper 4 weeksVisit

Short-form verdict pages comparing Foundayo to other GLP-1 options with trial-anchored data, FDA-label dosing, and current manufacturer pricing.

See all drug-vs-drug verdicts, or compare every weight loss medication we cover.

Real patient questions about Foundayo pulled from named subreddits and answered with peer-reviewed trial data.

Scannable cheat sheets for dose schedules, missed-dose rules, and red-flag side effects — every number verified against the DailyMed FDA label.

Curated lists of the highest-impact peer-reviewed studies on Foundayo and related GLP-1 drugs. Every PMID is checked against its PubMed record.

Deep-dive articles from our research desk with primary-source trial data, FDA label verification, and editorial analysis.

Orforglipron vs Rybelsus: How the Two Oral GLP-1 Pills Compare (2026)
Orforglipron (Foundayo) vs Rybelsus (oral semaglutide): a 2026 head-to-head on molecule type, indication, how you take each, effectiveness, cost, and side effects — and who should pick which.
9 min read4 citations
GLP-1 Pipeline Tracker: Every Next-Gen Weight-Loss Drug in Development (2026)
A tracker of next-generation GLP-1 and incretin drugs: retatrutide, CagriSema, MariTide, survodutide, amycretin, mazdutide, ecnoglutide and the approved oral pill orforglipron (Foundayo), with stage and peak reported weight loss.
7 min read19 citations
Mounjaro Alternatives (2026): T2D-Approved GLP-1s, Tirzepatide Cousins (Zepbound), and Off-Label vs On-Label Decisions
Mounjaro is approved only for type 2 diabetes, so the best alternative depends on your goal: Zepbound for the same tirzepatide with a weight label, other diabetes GLP-1s (Ozempic, Trulicity, Rybelsus, Victoza), or an on-label weight drug if you used Mounjaro off-label.
13 min read10 citations
Wegovy Alternatives (2026): Zepbound, Foundayo, Saxenda & Compounded Semaglutide
FDA-approved Wegovy alternatives are Zepbound for higher effect (SURMOUNT-1 -20.9% vs STEP-1 -14.9%), Foundayo as an oral option, Saxenda, and non-GLP-1 drugs such as Qsymia and Contrave. Compounded semaglutide is a cash-pay option with caveats.
12 min read7 citations
Zepbound Alternatives (2026): Wegovy, Foundayo, Compounded Tirzepatide & The Caremark Formulary Reality
The main Zepbound alternatives are Wegovy (−14.9% vs −20.9%, Caremark-preferred), Mounjaro (same drug, diabetes-only), Foundayo ($149/month pill) and compounded tirzepatide. For sleep apnea, no other drug is approved.
14 min read7 citations
Rybelsus Alternatives: When Oral Semaglutide Isn't Working — Switching to Foundayo, Wegovy, or Compounded (2026)
Rybelsus is approved only for type 2 diabetes and has strict fasting rules. When it isn't working, Foundayo (orforglipron) is the FDA-approved oral option for weight management, and Wegovy and Zepbound injections offer larger weight loss.
13 min read8 citations

Frequently Asked Questions

FDA-approved for chronic weight management in adults with obesity, or overweight with weight-related medical problems, alongside a reduced-calorie diet and increased physical activity (April 1, 2026). Not approved for pediatric use. Use with another GLP-1 receptor agonist is not recommended.
Among the 24 providers in the cost comparison table above, Foundayo's lowest ongoing monthly cash price is $149 and the highest is $499, depending on provider, form and dose. These are medication prices only — copays, membership fees and intro offers are excluded. Always check for manufacturer savings programs.
Common: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, swollen belly, fatigue, belching, heartburn, gas, hair loss. Serious: pancreatitis, dehydration leading to kidney problems, gallbladder disease, hypoglycemia (especially with insulin/sulfonylureas), serious allergic reactions, diabetic retinopathy progression in T2D patients, increased aspiration risk during anesthesia. Boxed warning: risk of thyroid C-cell tumors, carried as a GLP-1 class warning; orforglipron itself is not pharmacologically active in rats or mice and did not produce tumors in rodents. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Foundayo requires a prescription from a licensed healthcare provider. You can get it through your primary care doctor, endocrinologist, or a telehealth platform. The telehealth providers listed above prescribe it online.
Sources & methodology (as of November 2026)
  1. 1.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  2. 2.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  3. 3.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  4. 4.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  5. 5.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.